No. 38033

|  |  |  |
| --- | --- | --- |
| November 8, 2018 |  | Le 8 novembre 2018 |
|  |  |  |
| BETWEEN:  Teva Canada Limited  Applicant  - and -  Janssen Inc., Janssen-Ortho LLC, Janssen Pharmaceuticals, Inc., OMJ Pharmaceuticals, Inc. and Daiichi Sankyo Company, Limited  Respondents |  | ENTRE :  Teva Canada Limitée  Demanderesse  - et -  Janssen Inc., Janssen-Ortho LLC, Janssen Pharmaceuticals, Inc., OMJ Pharmaceuticals, Inc. et Daiichi Sankyo Company, Limited  Intimées |
|  |  |  |
| JUDGMENT  The motion to add Jansseen-Ortho LLC, Janssen Pharmaceuticals, Inc. and OMJ Pharmaceuticals, Inc. as parties to the application for leave to appeal is granted. The application for leave to appeal from the judgment of the Federal Court of Appeal, Number A-244-16, 2018 FCA 33, dated January 24, 2018, is dismissed with costs. |  | JUGEMENT  La requête en vue d’ajouter Jansseen-Ortho LLC, Janssen Pharmaceuticals, Inc. et OMJ Pharmaceuticals, Inc. comme parties à la demande d’autorisation d’appel est accueillie. La demande d’autorisation d’appel de l’arrêt de la Cour d’appel fédérale, numéro A-244-16, 2018 FCA 33, daté du 24 janvier 2018, est rejetée avec dépens. |

C.J.C.

J.C.C.